Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.

Journal: Antiviral therapy
PMID: 35485332

Abstract

BACKGROUND: This Phase I, two-part, first-in-human study assessed safety/tolerability and pharmacokinetics/pharmacodynamics of single-ascending doses (SAD) and multiple doses (MD) of the oral toll-like receptor-7 agonist, JNJ-64794964 (JNJ-4964) in healthy adults.

Authors

  • Edward Gane
    New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand.
  • Mina Pastagia
    333755Janssen BioPharma Inc., South San Francisco, CA, USA.
  • Ullrich Schwertschlag
    333755Janssen BioPharma Inc., South San Francisco, CA, USA.
  • An De Creus
    Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Christian Schwabe
    Auckland Clinical Studies, Auckland, New Zealand.
  • Joris Vandenbossche
    Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Leen Slaets
    Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Bart Fevery
    Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Ilham Smyej
    Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Liviawati S Wu
    333755Janssen BioPharma Inc., South San Francisco, CA, USA.
  • Rui Li
    Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing, China.
  • Samia Siddiqui
    Janssen Research & Development LLC, Titusville, NJ, USA.
  • Abbie Oey
    333755Janssen BioPharma Inc., South San Francisco, CA, USA.
  • Clark Musto
    333755Janssen BioPharma Inc., South San Francisco, CA, USA.
  • Pieter Van Remoortere
    Janssen Research & Development LLC, Titusville, NJ, USA.

Keywords

External Resources

Popular Topics
Recent Journals